Use of the Closure Device in Patient With Percutaneous Transfemoral Aortic Valve Replacement
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Safety endpoints during index hospitalisation
研究概览
简要总结
Use of the closure device in patient with percutaneous transfemoral aortic valve replacement
详细描述
The advent of endovascular, transcatheter aortic valve replacement (TAVR), and mechanical circulatory support has offered new, minimally invasive therapeutic options that are rapidly becoming standard of care. These percutaneous transfemoral interventions require large-bore catheters and have created challenges for femoral arterial access management. Current approaches include surgical cut-down with arterial puncture under direct vision, and suture-based "pre-closure." Surgical cut-down is associated with longer procedural time, increased patient discomfort, deeper anesthesia, risk of wound complications including infection, and slower ambulation. The pre-closure technique overcomes many of the disadvantages of surgical cut-down but can be technically demanding, time consuming, and associated with a significant failure rate. Recent randomized TAVR trials have reported major vascular complications in 6% to 8% . Furthermore, a study on the 2 suture-based closure techniques for management of TAVR access reported a 20% vascular complication rate despite being used by experienced operators . Currently, the majority of access site complications result from failed arteriotomy closure . The percutaneous MANTA Vascular Closure Device (VCD) (Essential Medical Inc., Malvern, Pennsylvania) is a novel collagen-based technology dedicated to closure of largebore arteriotomies . The MANTA VCD underwent prospective multicenter evaluation for Conformitä Europäenne (CE) mark approval in the first detailed report of outcomes achieved with a dedicated large-bore vascular closure device Contrary to the aforementioned TAVR procedures, mechanical circulatory support therapy can be extended up to several days on the intensive care ward. Data on such delayed closure with is lacking. This registry is therefore aimed to document the initial experiences of delayed closure of a femoral large bore access with vascular closure devices in patients with an TAVR device.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient scheduled for treatment with the TAVR device
- •Decision to use the Manta or the Prostar closure device on a clinical base by the treating physician
- •Signed informed consent
排除标准
- •Male or female aged < 18
- •Pregnant and lactating females
- •Patient has been committed to an institution by legal or regulatory order
结局指标
主要结局
Safety endpoints during index hospitalisation
时间窗: 2018 - 2020
Major vascular complications,
Safety endpoints during index hospitalisation ( bleeding)
时间窗: 2018-2020
life-threatining-, major bleeding
Safety endpoints during index hospitalisation ( death )
时间窗: 2018-2020
death
次要结局
- efficacy endpoints during index hospitalisation - (hemotasis)(2018-2020)
- efficacy endpoints during index hospitalisation ( device failure)(2018-2020)
- efficacy endpoints during index hospitalisation ( bail-out )(2018-2020)
研究者
Jörg Schröder
PD Dr. med Jörg Schröder
RWTH Aachen University
